(IVA) Inventiva S.A - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: PA (France) | Market Cap: 999m EUR | Total Return: 56.4% in 12m
Avg Turnover: 1.04M
Warnings
Negative Equity with losses - insolvent profile
Share dilution 1209.3% YoY
Interest Coverage Ratio -5.1 is critical
Altman Z'' -12.19 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Inventiva S.A. is a clinical-stage biopharmaceutical firm based in France specializing in oral small-molecule therapies. The company’s primary focus is the development of Lanifibranor, a pan-peroxisome proliferator-activated receptor (PPAR) agonist currently in Phase 3 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Its pipeline also includes Odiparcil for mucopolysaccharidoses and a pre-clinical program targeting idiopathic pulmonary fibrosis.
The biotechnology sector often faces high capital expenditures and long regulatory lead times, as clinical-stage companies typically rely on successful Phase 3 outcomes to transition toward commercialization. Inventiva’s business model centers on the pan-PPAR approach, which aims to activate three distinct nuclear receptors simultaneously to address the multi-factorial nature of fibrotic liver diseases. Investors may find additional valuation metrics and pipeline comparisons on ValueRay to further their analysis.
- Lanifibranor Phase 3 clinical trial results dictate long term commercial viability
- MASH market competition intensifies as rival therapies gain regulatory approval
- Cash runway and future financing needs impact near term share dilution
- Strategic partnerships and licensing agreements drive non-dilutive revenue growth
- Regulatory approval timeline for small molecule therapies influences valuation milestones
| Net Income: -538.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -2.11 > 0.02 and ΔFCF/TA 11.65 > 1.0 |
| NWC/Revenue: 869.9% < 20% (prev -5.10%; Δ 875.1% < -1%) |
| CFO/TA -0.77 > 3% & CFO -191.1m > Net Income -538.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (637.1m) vs 12m ago 1.21k% < -2% |
| Gross Margin: 79.37% > 18% (prev 0.96%; Δ 7.84k% > 0.5%) |
| Asset Turnover: 12.04% > 50% (prev 55.47%; Δ -43.43% > 0%) |
| Interest Coverage Ratio: -5.11 > 6 (EBITDA TTM -231.6m / Interest Expense TTM 45.8m) |
| A: 0.67 (Total Current Assets 244.5m - Total Current Liabilities 77.4m) / Total Assets 249.5m |
| B: -1.42 (Retained Earnings -354.1m / Total Assets 249.5m) |
| C: -1.47 (EBIT TTM -233.9m / Avg Total Assets 159.5m) |
| D: -2.00 (Book Value of Equity -556.8m / Total Liabilities 278.0m) |
| Altman-Z'' = -12.19 = D |
| DSRI: 1.17 (Receivables 9.12m/15.7m, Revenue 19.2m/38.6m) |
| GMI: 1.21 (GM 79.37% / 96.14%) |
| AQI: 0.05 (AQ_t 0.01 / AQ_t-1 0.18) |
| SGI: 0.50 (Revenue 19.2m / 38.6m) |
| TATA: -1.39 (NI -538.4m - CFO -191.1m) / TA 249.5m) |
| Beneish M = -5.06 (Cap -4..+1) = AAA |
As of May 24, 2026, the stock is trading at EUR 4.40 with a total of 128,120 shares traded.
Over the past week, the price has changed by -8.94%,
over one month by -3.95%,
over three months by -22.48% and
over the past year by +56.43%.
Inventiva S.A has no consensus analysts rating.
P/S = 147.7276
P/B = 2.0001
Revenue TTM = 19.2m EUR
EBIT TTM = -233.9m EUR
EBITDA TTM = -231.6m EUR
Long Term Debt = 26.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 32.3m EUR (from shortTermDebt, last quarter)
Debt = 62.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.77m
Net Debt = 31.3m EUR (calculated: Debt 62.6m - CCE 31.3m)
Enterprise Value = 1.03b EUR (998.8m + Debt 62.6m - CCE 31.3m)
Interest Coverage Ratio = -5.11 (Ebit TTM -233.9m / Interest Expense TTM 45.8m)
EV/FCF = -1.95x (Enterprise Value 1.03b / FCF TTM -527.5m)
FCF Yield = -51.21% (FCF TTM -527.5m / Enterprise Value 1.03b)
FCF Margin = -2.75k% (FCF TTM -527.5m / Revenue TTM 19.2m)
Net Margin = -2.80k% (Net Income TTM -538.4m / Revenue TTM 19.2m)
Gross Margin = 79.37% ((Revenue TTM 19.2m - Cost of Revenue TTM 3.96m) / Revenue TTM)
Gross Margin QoQ = none% (prev 61.74%)
Tobins Q-Ratio = 4.13 (Enterprise Value 1.03b / Total Assets 249.5m)
Interest Expense / Debt = 73.14% (Interest Expense 45.8m / Debt 62.6m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -175.4m (EBIT -233.9m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 2.36 (Total Current Assets 244.5m / Total Current Liabilities 103.4m)
Debt / Equity = -2.20 (negative equity) (Debt 62.6m / totalStockholderEquity, last quarter -28.5m)
Debt / EBITDA = -0.14 (negative EBITDA) (Net Debt 31.3m / EBITDA -231.6m)
Debt / FCF = -0.06 (negative FCF - burning cash) (Net Debt 31.3m / FCF TTM -527.5m)
Total Stockholder Equity = -55.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -337.4% (out of range, set to none)
RoE = -180.5% (Net Income TTM -538.4m / Total Stockholder Equity 298.2m)
RoCE = -71.95% (EBIT -233.9m / Capital Employed (Equity 298.2m + L.T.Debt 26.8m))
RoIC = -85.80% (negative operating profit) (NOPAT -175.4m / Invested Capital 204.4m)
WACC = 6.44% (E(998.8m)/V(1.06b) * Re(6.84%) + (debt cost/tax rate unavailable))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 247.4%
[DCF] Fair Price = unknown (Cash Flow -527.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.46 | # QB: 0
Revenue Correlation: -81.02 | Revenue CAGR: -41.09% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=-0.70 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+62.9% | GrowthRev=+20.8%
EPS next Year (2027-12-31): EPS=-0.76 | Chg30d=+0.00% | Revisions=-20% | GrowthEPS=-8.1% | GrowthRev=+2082.0%
[Analyst] Revisions Ratio: -20%